Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and CYP2D6 Contribution of Idalopirdine in Healthy Subjects
NCT02019394Phase 1Completed
- Sponsor
- Lundbeck
- Start
- Dec 2013
- Primary completion
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Idalopirdine in Alzheimer's disease (AD), sponsored by Lundbeck. Primary endpoints: Absolute bioavailability: (AUC0-24) Dose oral/(AUC0-inf) Dose IV at Day 10 and Ratio of (AUC0-24(PM)/AUC0-24(EM)) at Day 10. Started Dec 2013; status: completed.
02
Drugs
Idalopirdine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02019394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02019394.